Taiwan Approves NT$100 Million Gene Therapy for Rare AADC Deficiency Amid Coverage Debate
核心洞察
Taiwan's National Health Insurance Administration (搜索) approved coverage for a NT$100 million gene therapy (搜索) treating aromatic L-amino acid decarboxylase (搜索) (AADC) deficiency, a rare genetic disorder affecting infants.
The therapy, originally developed by National Taiwan University Hospital in 2007, showed remarkable results with 80% of trial patients able to sit up and 40% achieving independent walking after early treatment.
The decision sparked controversy over healthcare resource allocation, as physicians argue other rare diseases affecting more patients receive less comprehensive coverage despite lower costs.
Taiwan's National Health Insurance Administration (搜索) (NHIA (搜索)) has approved coverage for an expensive gene therapy (搜索) treating aromatic L-amino acid decarboxylase (搜索) (AADC) deficiency, marking a significant milestone for rare disease treatment while igniting debate over healthcare resource allocation and treatment equity.
The one-time therapy, costing approximately NT$100 million (US$3.28 million) per injection, will be covered on a temporary basis with effectiveness reassessed three years after treatment begins. AADC deficiency (搜索) affects infants and young children, causing severe developmental delays and autonomic dysfunction, with many patients dying between ages 2 and 5 without treatment.
Breakthrough Treatment Shows Remarkable Results
The therapy was originally developed by National Taiwan University Hospital (NTUH (搜索)) in 2007, with clinical protocols established in 2010 before being licensed to a U.S. company. Among 31 patients who received the therapy in trials, 80 percent were able to sit up, and among those treated early with intensive rehabilitation, 40 percent achieved independent walking.
"Just being able to sit up instead of only lying down makes an enormous difference," said NTUH (搜索) Department of Medical Genetics Director Chien Yin-hsiu. "For parents providing daily care, the improvement is like night and day."
Previously, no effective treatment existed for AADC deficiency (搜索), leaving affected children immobile in bed with no motor development. The gene therapy (搜索) can significantly improve motor function and quality of life for patients who would otherwise face severe disability or death.
Healthcare Resource Allocation Sparks Controversy
The NHIA (搜索) estimates 13 patients will receive the therapy in its first year at a cost of approximately NT$1.3 billion. From the second through fifth years, five additional patients are expected to be treated annually, costing roughly NT$500 million per year.
The decision has drawn criticism from physicians who question the allocation of healthcare resources. Pulmonologist Su Yi-fong noted that drugs for other rare diseases, such as lymphangioleiomyomatosis (搜索) (LAM (搜索) or "bubble lung"), treat dozens of patients for less than NT$100 million yet are not fully covered.
Regarding LAM (搜索) coverage, NHIA (搜索) Director-General Chen Lian-yu explained that the disease is not currently classified as rare, though applications have been submitted. Coverage will follow once the ministry completes its review. LAM drugs have been covered under NHI since 2001, with 26 patients reported last year.
Strategic Investment in Genetic Medicine
Supporters argue the AADC therapy investment extends beyond immediate patient benefits. Hospitalist Chiang Kuan-yu suggested the investment could help position Taiwan as a key site for Asian genetic data, supporting future research collaborations and negotiations with international pharmaceutical companies.
NTUH (搜索)'s Chien Yin-hsiu defended the technology transfer to the U.S., explaining that few believed in the feasibility of AADC gene therapy (搜索) two decades ago when the research began. The successful development demonstrates Taiwan's capabilities in advancing cutting-edge genetic therapies.
The NHIA (搜索) stated it will assist families facing difficulties in the application process, acknowledging the complex challenges surrounding rare disease treatment access and the need for comprehensive support systems beyond financial coverage.